ijms-logo

Journal Browser

Journal Browser

Bioactive Agents Effective in the Prevention of Metabolic Syndrome

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 25 July 2024 | Viewed by 2530

Special Issue Editor


E-Mail Website
Guest Editor
CPIRN-UDI/IPG—Centro de Potencial e Inovação em Recursos Naturais, Unidade de Investigação para o Desenvolvimento do Interior do Instituto Politécnico da Guarda, 6300-559 Guarda, Portugal
Interests: bioactive compounds as health promoters; natural products; medicinal plants; bioactivity; in vivo assays; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bioactive compounds are the food constituents that provide beneficial health effects to functional foods and nutraceuticals. These compounds exhibit antioxidant, anti-inflammatory, and antifungal ctivities as well as additional preventative properties. They are also the target mechanisms that manage, prevent, and/or treat chronic or acute disorders. Metabolic syndrome is a clinical syndrome characterised by several comorbidities, including abdominal obesity, arterial hypertension, dyslipidemia and hyperglycemia, which together represent an important risk factor for the onset of cardiovascular diseases and premature death, as well as have a significant impact on healthcare costs. Bioative compounds are an effective weapon in the battle against metabolic syndrome.

In this regard, the consumption of functional foods and natural bioactive compounds may have a positive impact on body weight, blood pressure and glucose metabolism control, endothelial damage, lipid profile improvement, inflammation, and oxidative stress.

Dr. Luís R. Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic syndrome
  • bioactive compounds
  • cardiovascular disease
  • diabetes mellitus
  • inflammation
  • functional foods
  • obesity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1559 KiB  
Article
Protective Effect of Betulin on Streptozotocin–Nicotinamide-Induced Diabetes in Female Rats
by Feyisayo O. Adepoju, Ksenia V. Sokolova, Irina F. Gette, Irina G. Danilova, Mikhail V. Tsurkan, Alicia C. Mondragon, Elena G. Kovaleva and Jose Manuel Miranda
Int. J. Mol. Sci. 2024, 25(4), 2166; https://doi.org/10.3390/ijms25042166 - 10 Feb 2024
Viewed by 1734
Abstract
Type 2 diabetes is characterized by hyperglycemia and a relative loss of β–cell function. Our research investigated the antidiabetic potential of betulin, a pentacyclic triterpenoid found primarily in birch bark and, intriguingly, in a few marine organisms. Betulin has been shown to possess [...] Read more.
Type 2 diabetes is characterized by hyperglycemia and a relative loss of β–cell function. Our research investigated the antidiabetic potential of betulin, a pentacyclic triterpenoid found primarily in birch bark and, intriguingly, in a few marine organisms. Betulin has been shown to possess diverse biological activities, including antioxidant and antidiabetic activities; however, no studies have fully explored the effects of betulin on the pancreas and pancreatic islets. In this study, we investigated the effect of betulin on streptozotocin–nicotinamide (STZ)-induced diabetes in female Wistar rats. Betulin was prepared as an emulsion, and intragastric treatments were administered at doses of 20 and 50 mg/kg for 28 days. The effect of treatment was assessed by analyzing glucose parameters such as fasting blood glucose, hemoglobin A1C, and glucose tolerance; hepatic and renal biomarkers; lipid peroxidation; antioxidant enzymes; immunohistochemical analysis; and hematological indices. Administration of betulin improved the glycemic response and decreased α–amylase activity in diabetic rats, although insulin levels and homeostatic model assessment for insulin resistance (HOMA–IR) scores remained unchanged. Furthermore, betulin lowered the levels of hepatic biomarkers (aspartate aminotransferase, alanine aminotransferase, and alpha-amylase activities) and renal biomarkers (urea and creatine), in addition to improving glutathione levels and preventing the elevation of lipid peroxidation in diabetic animals. We also found that betulin promoted the regeneration of β–cells in a dose-dependent manner but did not have toxic effects on the pancreas. In conclusion, betulin at a dose of 50 mg/kg exerts a pronounced protective effect against cytolysis, diabetic nephropathy, and damage to the acinar pancreas and may be a potential treatment option for diabetes. Full article
(This article belongs to the Special Issue Bioactive Agents Effective in the Prevention of Metabolic Syndrome)
Show Figures

Figure 1

Back to TopTop